News

Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy

Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy

Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics’ iPSC cell line.
Cartherics, The University of Queensland and The University of Sydney enter Material Transfer Agreement to support development of iPSC-derived cardiomyocytes for the treatment of cardiovascular disease.

Melbourne, Australia, 25 July 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), […]

Christine Filippis2024-07-25T13:12:43+10:00July 25th, 2024|

Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work in developing cell therapy treatments for cancer. He discusses Cartherics’ expanding intellectual property portfolio, the impact of targeting TAG-72 on treating ovarian and gastric cancers as well as recent collaborations and the growing market for […]

Christine Filippis2024-06-14T16:20:03+10:00June 14th, 2024|

Cartherics secures Australian patent for innovative cancer cell therapy

Cartherics secures Australian patent for innovative cancer cell therapy

Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its first Australian patent, AU2016361451, entitled “Genetically modified cells and uses thereof”, providing patent support for multiple development candidates in the […]

Christine Filippis2024-06-12T13:49:21+10:00June 12th, 2024|

Cartherics granted European patent for multiple development candidates

Cartherics granted European patent for multiple development candidates

Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.

The European Patent No. 3708587 B1, titled ‘Genetically […]

Christine Filippis2024-05-23T15:21:41+10:00May 23rd, 2024|

Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer

Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer

Cartherics’ CEO, Prof. Alan Trounson AO recently presented at Private Capital 2024 held at the ASX Building in Sydney. During his presentation, Alan delves into Cartherics‘ pioneering technology

Christine Filippis2024-06-14T15:02:52+10:00May 22nd, 2024|

Cartherics: An Innovative Company Developing Cellular Immunotherapy Cancer Treatments

Cartherics: An Innovative Company Developing Cellular Immunotherapy Cancer Treatments

Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics’ innovative approach to using stem cells to develop new cancer therapies. Alan’s leadership and expertise underscore the company’s commitment to advancing cancer treatment and improving outcomes for patients. Read the article here: https://pulse2.com/cartherics-prof-alan-trounson-profile/

Christine Filippis2024-05-14T13:54:09+10:00May 14th, 2024|

The first baby from a frozen embryo turns 40!

The first baby from a frozen embryo turns 40!

Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of German, Austrian and Swiss newspapers. Barbara’s article, translated below, was published in a number of European newspapers, highlighting that the first baby born from a frozen embryo is now 40 years old – a result […]

Christine Filippis2024-05-02T14:08:41+10:00May 2nd, 2024|

Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)

Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)

Ian Nisbet, PhD

Chief Operating Officer, Cartherics Pty Ltd

As published in pharmaphorum

Background

The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to Antibody-Drug Conjugates (ADCs), highlighting their potential in cancer therapy [1, 2]. This development serves as an opportunity for companies to reflect on the […]

Christine Filippis2024-04-26T12:20:09+10:00April 26th, 2024|

Cartherics enters into Collaborative Research Agreement with TiCARos

Cartherics enters into Collaborative Research Agreement with TiCARos

Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer […]

Christine Filippis2024-04-02T13:48:04+11:00April 2nd, 2024|

Cartherics executes Option Agreement with The Ohio State University

Cartherics executes Option Agreement with The Ohio State University

TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS

Melbourne, Australia, 20 March 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP) from The Ohio State University (Ohio […]

Christine Filippis2024-03-20T12:56:13+11:00March 20th, 2024|

About us

Sign up to our newsletter